CTXR · Citius Pharmaceuticals, Inc. · Executive Compensation
$0.52
-0.01 (-2.18%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company estimates that its and Citius Oncology's collective available cash resources will be sufficient to fund our operations through November 2026. We will need to raise additional capital in the future to support our operations beyond November 2026, which raises substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$15.38M
Shares
27.45M
Volume · Oct 5
132.55K
Avg daily vol (3M)
520.5K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Leonard Mazur | Chief Executive Officer and Executive Chairman | $3,521,268 |
| Myron Holubiak | Executive Vice Chairman | $2,199,588 |
| Jaime Bartushak | Chief Financial Officer and Chief Business Officer | $1,733,514 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Leonard Mazur | Chief Executive Officer and Executive Chairman | $1,981,113 |
| Myron Holubiak | Executive Vice Chairman | $1,594,373 |
| Myron S. Czuczman | Chief Medical Officer and Executive Vice President | $1,170,502 |
| Jaime Bartushak | Chief Financial Officer and Chief Business Officer | $1,145,274 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Myron Holubiak | Executive Vice Chairman | $1,240,056 |
| Leonard Mazur | Chief Executive Officer and Executive Chairman | $1,190,056 |
| Myron S. Czuczman | Chief Medical Officer and Executive Vice President | $887,846 |